A Clinical Manifesto on SGLT2 Inhibitors in Patients With Heart Failure

Published: 25 August 2020

  • Views:

    Views Icon 140
  • Likes:

    Heart Icon 1

Overview

Full programme

  • Views:

    Views Icon 140
  • Likes:

    Heart Icon 1

Overview

This educational symposium was part of the eSPACE Heart Failure meeting held 11-14 July 2020. 

 

The session focuses on latest data and practical implication of SGLT2 Inhibitors in Heart Failure patients.

These videos were funded by an unrestricted educational grant from Boehringer Ingelheim & Eli Lilly and Company.

Learning objectives

  • Encourage conversation around SGLT2 inhibitors as cardiovascular therapies with cardio–renal benefits
  • Highlight and discuss profiles of appropriate patients for initiation of an SGLT2 inhibitor, and share with cardiologists the well-established safety profile of and the clinical considerations for treatment with an SGLT2 inhibitor
  • Inform cardiologists of the current evidence and ongoing trials for SGLT2 inhibitors in patients with heart failure

Symposium Agenda

Time - Session title and objective - Speaker(s)

  • 25 mins - Health: SGLT2 inhibitors and quality of life - Martin Cowie, Shelley Zieroth
  • 5 mins - Transition
  • 25 mins - Protect: SGLT2 inhibitors in patients with HF - Martin Cowie, Nikolaus Marx
  • 5 mins - Transition
  • 25 mins - Wealth: An abundance (and more to come) of SGLT2 inhibitor evidence - Stefan Anker, Andrew Coats
  • 5 mins - Close

Series overview

Part 1

Welcome & Introductions

1 session

Part 2

Health: SGLT2 Inhibitors and Quality of Life

1 session

  • Health: SGLT2 Inhibitors and Quality of Life

    Watch now

Part 3

Protect: SGLT2 Inhibitors in Patients with HF

1 session

  • Protect: SGLT2 Inhibitors in Patients with HF

    Watch now

Part 4

Wealth: An Abundance (and More to Come) of SGLT2 Inhibitor Evidence

1 session

  • Wealth: An Abundance (and More to Come) of SGLT2 Inhibitor Evidence

    Watch now

Part 5

Panel Discussion

1 session

Faculty biographies